Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. provided unaudited consolidated earnings guidance for the year ended December 31, 2018. For the year, the company expected that the revenue of the Group will record an increase by approximately 50% and the net profit of the Group will record an increase over 50% for the year ended December 31, 2018 as compared to that for the year ended December 31, 2017. Sales of the Group's major products were in good condition, which ensured the steady increase in their revenue.